The impending publication of the fifth edition of the American
Psychiatric Association’s (APA) Diagnostic and Statistical Manual of
Mental Disorders (DSM-V) may affect diagnosis rates of conditions such
as Attention-Deficit/Hyperactivity Disorder (ADHD), both in the US and
worldwide.
European countries are increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more and more diagnoses of ADHD. This may eventually result in a rise in ADHD diagnoses even further afield.
Although Europe trails behind the US in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over 2012-2018, beating the US CAGR of 6% during the same future period. European markets have not yet neared the saturation point that ADHD therapeutics are facing in the US, and there is an optimistic view for ambitious growth in this region. The ADHD therapeutics market across France, Germany, Italy, Spain and the UK is predicted to reach approximately $182m in 2018.
Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=99800
This report “ADHD Therapeutics Market to 2018 – New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment” provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.
Scope:
European countries are increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more and more diagnoses of ADHD. This may eventually result in a rise in ADHD diagnoses even further afield.
Although Europe trails behind the US in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over 2012-2018, beating the US CAGR of 6% during the same future period. European markets have not yet neared the saturation point that ADHD therapeutics are facing in the US, and there is an optimistic view for ambitious growth in this region. The ADHD therapeutics market across France, Germany, Italy, Spain and the UK is predicted to reach approximately $182m in 2018.
Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=99800
This report “ADHD Therapeutics Market to 2018 – New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment” provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.
Scope:
- Current and future treatment and diagnosis trends for ADHD
- Market forecasts for ADHD across seven major markets
- Analysis of the developmental pipelines for ADHD
- Information on recent industry deals
- Understand how the ADHD market has developed and is continuing to develop within the featured markets
- Predict which products are likely to be most successful in the future
- Gain an understanding of the possible market available for specific products
No comments:
Post a Comment
Note: only a member of this blog may post a comment.